We simply cannot avoid all risks and the stakes are high in the biopharmaceutical industry. With patients’ lives dependent on a continuous supply of high-quality drugs and vaccines, it is essential to have consistency within the industry on how to manage risks. Today’s business environment requires that executives evaluate risks and have a well-defined strategy for managing them. There must also be a clear understanding and engagement from all business functions in order to succeed. This white paper focuses on how commercial, manufacturing, and supply aspects can be managed more successfully to mitigate risk.
June 28, 2017